Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Milioli H, Alexandrou S, Lim E, Caldon CE.

Endocr Relat Cancer. 2020 Feb 1. pii: ERC-19-0501.R1. doi: 10.1530/ERC-19-0501. [Epub ahead of print] Review.


Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.

Achinger-Kawecka J, Valdes-Mora F, Luu PL, Giles KA, Caldon CE, Qu W, Nair S, Soto S, Locke WJ, Yeo-Teh NS, Gould CM, Du Q, Smith GC, Ramos IR, Fernandez KF, Hoon DS, Gee JMW, Stirzaker C, Clark SJ.

Nat Commun. 2020 Jan 16;11(1):320. doi: 10.1038/s41467-019-14098-x.


Targeting CDK2 in cancer: challenges and opportunities for therapy.

Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S.

Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001. Epub 2019 Dec 10. Review.


MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma.

Castillo L, Young AIJ, Mawson A, Schafranek P, Steinmann AM, Nessem D, Parkin A, Johns A, Chou A, Law AMK, Lucas MC, Murphy KJ, Deng N, Gallego-Ortega D, Caldon CE; Australian Pancreatic Cancer Genome Initiative (APGI), Timpson P, Pajic M, Ormandy CJ, Oakes SR.

Oncogene. 2020 Feb;39(8):1821-1829. doi: 10.1038/s41388-019-1091-0. Epub 2019 Nov 18.


Label free, quantitative single-cell fate tracking of time-lapse movies.

Caldon CE, Burgess A.

MethodsX. 2019 Oct 18;6:2468-2475. doi: 10.1016/j.mex.2019.10.014. eCollection 2019.


Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer.

Currey N, Jahan Z, Caldon CE, Tran PN, Benthani F, De Lacavalerie P, Roden DL, Gloss BS, Campos C, Bean EG, Bullman A, Reibe-Pal S, Dinger ME, Febbraio MA, Clarke SJ, Dahlstrom JE, Kohonen-Corish MRJ.

Cell Mol Gastroenterol Hepatol. 2019;7(4):819-839. doi: 10.1016/j.jcmgh.2019.01.009. Epub 2019 Mar 2.


The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE.

Int J Mol Sci. 2019 Feb 4;20(3). pii: E667. doi: 10.3390/ijms20030667. Review.


Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer.

Du Q, Bert SA, Armstrong NJ, Caldon CE, Song JZ, Nair SS, Gould CM, Luu PL, Peters T, Khoury A, Qu W, Zotenko E, Stirzaker C, Clark SJ.

Nat Commun. 2019 Jan 24;10(1):416. doi: 10.1038/s41467-019-08302-1.


Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.

Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333.


Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.

Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE.

Endocr Relat Cancer. 2019 Jan;26(1):R15-R30. doi: 10.1530/ERC-18-0317. Review.


19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.

Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R; Australian Ovarian Cancer Study Group, Bowtell D, Waring P.

Gynecol Oncol. 2018 Nov;151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. Epub 2018 Sep 9.


Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.


MASTL overexpression promotes chromosome instability and metastasis in breast cancer.

Rogers S, McCloy RA, Parker BL, Gallego-Ortega D, Law AMK, Chin VT, Conway JRW, Fey D, Millar EKA, O'Toole S, Deng N, Swarbrick A, Chastain PD, Cesare AJ, Timpson P, Caldon CE, Croucher DR, James DE, Watkins DN, Burgess A.

Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.


Andy's Algorithms: new automated digital image analysis pipelines for FIJI.

Law AMK, Yin JXM, Castillo L, Young AIJ, Piggin C, Rogers S, Caldon CE, Burgess A, Millar EKA, O'Toole SA, Gallego-Ortega D, Ormandy CJ, Oakes SR.

Sci Rep. 2017 Nov 16;7(1):15717. doi: 10.1038/s41598-017-15885-6.


PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells.

Rogers S, Fey D, McCloy RA, Parker BL, Mitchell NJ, Payne RJ, Daly RJ, James DE, Caldon CE, Watkins DN, Croucher DR, Burgess A.

J Cell Sci. 2016 Apr 1;129(7):1340-54. doi: 10.1242/jcs.179754. Epub 2016 Feb 12.


Cdk2 regulates metastasis suppressor BRMS1.

Caldon CE.

Cell Cycle. 2016;15(6):779-80. doi: 10.1080/15384101.2015.1136521. No abstract available.


Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.

Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, Burgess A, Caldon CE.

Cell Div. 2015 Feb 19;10:1. doi: 10.1186/s13008-015-0007-9. eCollection 2015.


The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.

Susanto JM, Colvin EK, Pinese M, Chang DK, Pajic M, Mawson A, Caldon CE, Musgrove EA, Henshall SM, Sutherland RL, Biankin AV, Scarlett CJ.

Int J Oncol. 2015 May;46(5):2223-30. doi: 10.3892/ijo.2015.2894. Epub 2015 Feb 16.


Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast.

Loh SF, Cooper C, Selinger CI, Barnes EH, Chan C, Carmalt H, West R, Gluch L, Beith JM, Caldon CE, O'Toole S.

J Clin Pathol. 2015 Mar;68(3):187-91. doi: 10.1136/jclinpath-2014-202331. Epub 2014 Dec 12.


Estrogen signaling and the DNA damage response in hormone dependent breast cancers.

Caldon CE.

Front Oncol. 2014 May 14;4:106. doi: 10.3389/fonc.2014.00106. eCollection 2014. Review.


Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events.

McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A.

Cell Cycle. 2014;13(9):1400-12. doi: 10.4161/cc.28401. Epub 2014 Mar 6.


BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.

Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA.

Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16.


Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):606-17. doi: 10.4161/cc.23512. Epub 2013 Jan 16.


Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Caldon CE, Sergio CM, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):596-605. doi: 10.4161/cc.23409. Epub 2013 Jan 16.


ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.


Functional characterization of cancer-associated Gab1 mutations.

Ortiz-Padilla C, Gallego-Ortega D, Browne BC, Hochgräfe F, Caldon CE, Lyons RJ, Croucher DR, Rickwood D, Ormandy CJ, Brummer T, Daly RJ.

Oncogene. 2013 May 23;32(21):2696-702. doi: 10.1038/onc.2012.271. Epub 2012 Jul 2.


Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.


Cyclin D as a therapeutic target in cancer.

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL.

Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090. Review.


The antiproliferative effects of progestins in T47D breast cancer cells are tempered by progestin induction of the ETS transcription factor Elf5.

Hilton HN, Kalyuga M, Cowley MJ, Alles MC, Lee HJ, Caldon CE, Blazek K, Kaplan W, Musgrove EA, Daly RJ, Naylor MJ, Graham JD, Clarke CL, Ormandy CJ.

Mol Endocrinol. 2010 Jul;24(7):1380-92. doi: 10.1210/me.2009-0516. Epub 2010 Jun 2.


Cell cycle proteins in epithelial cell differentiation: implications for breast cancer.

Caldon CE, Sutherland RL, Musgrove E.

Cell Cycle. 2010 May 15;9(10):1918-28. Epub 2010 May 15. Review.


Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Caldon CE, Musgrove EA.

Cell Div. 2010 Jan 17;5:2. doi: 10.1186/1747-1028-5-2.


Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Caldon CE, Sergio CM, Schütte J, Boersma MN, Sutherland RL, Carroll JS, Musgrove EA.

Mol Cell Biol. 2009 Sep;29(17):4623-39. doi: 10.1128/MCB.00269-09. Epub 2009 Jun 29.


Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.

Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schütte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ, Sutherland RL.

PLoS One. 2008 Aug 20;3(8):e2987. doi: 10.1371/journal.pone.0002987.


Cell cycle machinery: links with genesis and treatment of breast cancer.

Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL.

Adv Exp Med Biol. 2008;630:189-205. Review.


The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.

Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA.

Cancer Res. 2008 Apr 15;68(8):3026-36. doi: 10.1158/0008-5472.CAN-07-3079.


Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation.

Caldon CE, Lee CS, Sutherland RL, Musgrove EA.

Oncogene. 2008 Jan 3;27(1):126-38. Epub 2007 Jun 25.


Cell cycle control in breast cancer cells.

Caldon CE, Daly RJ, Sutherland RL, Musgrove EA.

J Cell Biochem. 2006 Feb 1;97(2):261-74. Review.


Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein.

Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA, Daly RJ.

J Biol Chem. 2006 Jan 6;281(1):626-37. Epub 2005 Oct 27.


Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria.

Nadkarni MA, Caldon CE, Chhour KL, Fisher IP, Martin FE, Jacques NA, Hunter N.

J Clin Microbiol. 2004 Nov;42(11):5238-44.


Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.

Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ, Sutherland RL, Musgrove EA.

Oncogene. 2005 Jan 13;24(3):381-9.


Functional interaction of 13 yeast SCF complexes with a set of yeast E2 enzymes in vitro.

Kus BM, Caldon CE, Andorn-Broza R, Edwards AM.

Proteins. 2004 Feb 15;54(3):455-67.


Function of the universally conserved bacterial GTPases.

Caldon CE, March PE.

Curr Opin Microbiol. 2003 Apr;6(2):135-9. Review.


Evolution of a molecular switch: universal bacterial GTPases regulate ribosome function.

Caldon CE, Yoong P, March PE.

Mol Microbiol. 2001 Jul;41(2):289-97. Review.

Supplemental Content

Loading ...
Support Center